Viva Biotech Holdings provided earnings guidance for the six months ended June 30, 2019. For the period, the group is expected to record an increase of approximately 84% in its revenue for the six months ended June 30, 2019 as compared to that for the six months ended June 30, 2018 and an increase of approximately 47% in net profit excluding extraordinary profit or loss as compared to the Corresponding Period Last Year, of which net profit of the cash-for-service (CFS) business registered substantial growth, up approximately 187% from the Corresponding Period Last Year.